A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Completed · Phase 1/Phase 2
Conditions studied: Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic Syndrome (MDS), Preleukemia, Primary Myelofibrosis, Myeloproliferative Disorders, Bone Marrow Disease, Hematological Disease, Precancerous Conditions, Neoplasms, Leukemia, Neoplasms by Histologic Type, Essential Thrombocytosis
In brief
Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms. Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia). Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Key facts
- Study ID
- NCT02158858
- Run by
- Constellation Pharmaceuticals
- People needed
- 336
- Starts
- 2014-07-16
- Expected to finish
- 2025-01-09
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Arizona — Phoenix, Arizona, United States
- UCLA Medical Center — Los Angeles, California, United States
- Mayo Clinic Jacksonville — Jacksonville, Florida, United States
- Northwestern University - Lurie Comprehensive Cancer Center — Chicago, Illinois, United States
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- University of Michigan Medical Center — Ann Arbor, Michigan, United States
- Washington University School of Medicne Neuromuscular Division Department of Neurology Research — St Louis, Missouri, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- ICAHN School of Medicine at Mount Sinai — New York, New York, United States
- Weill Medical College and New York Presbyterian Hospital — New York, New York, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Froedtert & Medical College of Wisconsin — Milwaukee, Wisconsin, United States
- UZ Leuven - Campus Gasthuisberg — Leuven, Viaams Braban, Belgium
- AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan — Bruges, West-Vlaanderen, Belgium
- ZNA Stuyvenberg Antwerpen — Antwerp, Belgium
- University of Alberta Hospital — Edmonton, Alberta, Canada
- St. Paul's Hospital — Vancouver, British Columbia, Canada
- Juravinski Cancer Centre — Hamilton, Ontario, Canada
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Jewish General Hospital — Montreal, Quebec, Canada
- Institut de cancérologie du Gard - Hematologie clinique — Nîmes, Gard, France
- CHRU de Lille - Hopital Claude Huriez — Toulouse, Haute-Garonne, France
- CHRU de Lille - Hopital Claude Huriez - Maladies du Sang — Lille, Hauts-de-France, France
- CHU - Hopital Saint Louis - Centre D'Investigations Clinique — Paris, France
- Institut Gustave Roussy — Villejuif, Île-de-France Region, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.